Olon

Olon is a well-established, privately-held Italian company that has grown over five decades into a major global supplier and CDMO for Active Pharmaceutical Ingredients. Its business model is purely service and manufacturing-based, providing development and production capabilities from early-phase to commercial supply for both novel chemical entities (via CDMO) and generic drugs. With 14 manufacturing sites, 14 R&D centers, and approximately 2,800 employees, Olon leverages a dual-technology platform of chemical synthesis and biomanufacturing to offer flexible, scalable solutions. The company is actively pursuing innovation through strategic partnerships in areas like biocatalysis and green chemistry to strengthen its market position.

Integrated chemical synthesis and microbial biomanufacturing (fermentation) platform for API production, with emerging expertise in industrial biocatalysis and sustainable protein manufacturing.

Olon competes in a fragmented but competitive global API and CDMO market against large players like Lonza, Catalent, and Siegfried, as well as numerous specialized and low-cost manufacturers. Its differentiation is based on integrated chemical/biological expertise, a long industry track record, and a strategic focus on green chemistry and biocatalysis innovations.